GLP-1 receptor agonists (e.g., semaglutide) demonstrate cardiovascular benefits beyond glucose control. Which mechanism is responsible for the heart failure benefit seen in these agents?
- A Direct negative chronotropic effect on the SA node via GLP-1 receptors
- B Weight loss, blood pressure reduction, and reduced epicardial fat inflammation; also reduction in pericardial fat improving cardiac geometry ✓
- C Inhibition of SGLT1 in cardiomyocytes reducing calcium overload
- D Direct inotropic effect on ventricular cardiomyocytes via GLP-1R-cAMP pathway
Explanation
GLP-1 receptor agonists' cardiovascular benefits are primarily mediated through indirect mechanisms: significant body weight reduction (reducing cardiac preload and afterload), blood pressure lowering, reduction in epicardial and pericardial adipose tissue (which is a source of inflammatory cytokines), and favorable effects on dyslipidemia and inflammation. The direct cardiac GLP-1R-cAMP effect does cause modest positive inotropy (option D has some basis) but the dominant clinical benefit pathway is through cardiometabolic risk factor reduction and adipose tissue effects. The SUSTAIN-6 and LEADER trials demonstrated MACE reduction, with SELECT trial showing HFpEF benefit from semaglutide.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.